anti-ccr8 monoclonal antibody zl-1218
Generic: Anti-CCR8 Monoclonal Antibody ZL-1218
anti-ccr8 monoclonal antibody zl-1218: 1 clinical trial tracked.
anti-ccr8 monoclonal antibody zl-1218 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-ccr8 monoclonal antibody zl-1218, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
Clinical Trial Registry Records (1)
A Phase I, Open-label, Multicenter Study of ZL-1218 as a Single Agent and as Combination Therapy With Anti-PD-1 Antibody to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects With Advanced Solid Tumor Malignancies
Primary endpoint: Incidence of Dose Limiting Toxicities
Interventionalopen34 targetStarted 2023-07Completion 2025-0815 sites · China, Spain, United StatesZai Lab (Hong Kong), Ltd.